BioCentury
ARTICLE | Clinical News

Tibotec Phase II HIV data

February 9, 2001 8:00 AM UTC

Tibotec (Mechelen, Belgium) said that in a double-blind, placebo-controlled Phase II study in 43 treatment-naive HIV patients, its TMC120 non-nucleoside reverse transcriptase inhibitor gave a mean 1.5...